泰德医药（浙江）股份有限公司（03880）于2026年2月4日发布截至2026年1月31日的月报。公告显示，公司已发行股本总数维持不变，H股和非上市股份数量无新增发行或回购活动，股本结构整体保持稳定。
公司现有注册及已发行H股73,598,888股，无库存股；另有非上市股份68,201,112股，截至报告期末，两类股份合计141,800,000股。月报指出，报告期内未发生股份期权、权证或可转债的授予、行使或到期，也无任何购回、注销及转让安排。
公司在公告中确认，已遵守香港联合交易所有限公司证券上市规则及相关法律法规规定，所有股份变动事项均经董事会授权并符合上市守则要求。公告由联席公司秘书吴东澄签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.